四种基于MELD的评分系统对慢加急性乙型肝炎肝衰竭患者短期生存的预测价值分析*

doi:10.3969/j.issn.1672-5069.2018.03.025

摘要/Abstract

摘要： 目的比较终末期肝病模型（MELD）及其衍生模型iMELD、MELD-Na和MESO对乙型肝炎相关性慢加急性肝衰竭（HBV-ACLF）患者12周生存预后的评估价值。方法按照现行中国肝衰竭诊治指南的诊断标准纳入67例HBV-ACLF患者,收集患者诊断成立时的相关实验室检测指标,分别计算MELD、iMELD、MELD-Na和MESO模型评分,应用MedCalc 15.8软件分析比较受试者工作特征曲线（ROC）,确定MELD及其衍生评分系统对ACLF患者12周死亡风险预测的最佳截断点和约登指数,以评价不同评分预测ACLF患者短期生存的效能。结果在治疗12周内,在67例HBV-ACLF患者中,死亡45例（67.2%）;入组时,生存组MELD、iMELD、MELD-Na和MESO评分分别为（22.12±3.24）、（41.59±5.30）、（22.55±4.07）和（1.64±0.24）,显著低于死亡组【分别为（30.47±9.01）、（51.88±11.09）、（32.35±11.58）和（2.28±0.70）,P<0.01】;MELD、iMELD、MELD-Na和MESO模型预测患者12周生存的ROC曲线下面积分别为0.814、0.802、0.806和0.817,其最佳截断点分别为22.70、47.76、22.16和1.69,约登指数分别为0.5040、0.5535、0.4808和0.4818,提示四种模型的预测效能比较,均无显著性差异（P>0.05）。结论 MELD、iMELD、MELD-Na和MESO四种评分系统对于HBV-ACLF患者12周生存情况均具有良好的预测能力,可根据实际情况,选择应用。

关键词: 慢加急性肝衰竭, 乙型肝炎, 终末期肝病模型, 预后

Abstract: Objective To validate the prediction of short-term survival by four scoring systems based on models for end-stage liver disease（MELD） in patients with acute-on-chronic hepatitis B-induced liver failure （HBV-ACLF）. Methods 67 patients with HBV-ACLF were enrolled in this study between April 2015 and October 2017. The clinical parameters were collected for calculation of MELD,iMELD,MELD-Na and MESO scores,respectively. The predictive efficacy on forecasting survival of patients with HBV-ACLF by the four scoring systems was analyzed by receiver operating characteristic curve（ROC） supported by MedCalc15.8 software. Results 45（67.2%） out of 67 patients with HBV-ACLF died within 12 weeks;the scores of MELD,iMELD,MELD-Na and MESO models at presentation in survival group were （22.12±3.24）,（41.59±5.30）,（22.55±4.07） and （1.64±0.24）,much lower than 【（30.47±9.01）,（51.88±11.09）,（32.35±11.58） and （2.28±0.70）,respectively,P<0.01】 in the dead group;the area under the ROC curve （AUC） in forecasting the survival of patients with HBV-ACLF by the four models were 0.814,0.802,0.806 and 0.817 respectively,the cut-off-values were 22.70,47.76,22.16 and 1.69,and the Jordan index were 0.5040,0.5535,0.4808 and 0.4818,respectively,suggesting no significant differences between them（P>0.05）. Conclusion The four scoring systems base on MELD have good predictive efficacy on forecasting 12 weeks’ survival in patients with HBV-ACLF,which hints they might be applied in clinical practice.

Key words: Acute-on-chronic liver failure, Hepatitis B, Models for end-stage liver disease, Prognosis

李磊, 胡辉, 郑晓玮, 江守伟, 沈强. 四种基于MELD的评分系统对慢加急性乙型肝炎肝衰竭患者短期生存的预测价值分析*[J]. 实用肝脏病杂志, 2018, 21(3): 417-420.

Li Lei, Hu Hui, Zheng Xiaowei, et al. Prediction of short-term survival by four scoring systems based on MELD in patients with acute-on-chronic hepatitis B-induced liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 417-420.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南. 实用肝脏病杂志,2013,16(3):210-216.
[2] Malinchoc M,Kamath PS,Gordon FD,et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology,2000,31(4):864-871.
[3] Kamath PS,Wiesner RH, Malinchoc M,et al.A model to predict survival in patients with end-stage liver disease. Hepatology,2001,33(2):464-470.
[4] Zhou XD,Chen QF,Zhang MC,et al.Scoring model to predict outcome in critically ill cirrhotic patients with acute respiratory failure:comparison with MELD scoring models and CLIF-SOFA score. Expert Rev Gastroenterol Hepatol,2017,11(9):857-864.
[5] Choudhury A,Jindal A,Maiwall R,et al.Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF):comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int,2017,11(5):461-471.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[7] Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
[8] Jalan R,Yurdaydin C,Bajaj JS,et al.Toward an improved definition of acute-on-chronic liver failure. Gastroenterology,2014,147(1):4-10.
[9] Durand F,Nadim MK.Management of acute-on-chronic liver failure. Semin Liver Dis,2016,36(2):141-152.
[10] Arroyo V,Jalan R.Acute-on-chronic liver failure:Definition,diagnosis,and clinical characteristics. Semin Liver Dis,2016,36(2):109-116.
[11] Chaurasia RK,Pradhan B,Chaudhary S,et al.Child-Turcotte-Pugh versus model for end stage liver disease score for predicting survival in hospitalized patients with decompensated cirrhosis. J Nepal Health Res Counc,2013,11(23):9-16.
[12] Lee YH,Hsu CY,Huo TI.Assessing liver dysfunction in cirrhosis:role of the model for end-stage liver disease and its derived systems. J Chin Med Assoc,2013,76(8):419-424.
[13] El-Ghannam MT,Hassanien MH,El-Talkawy MD,et al. Performance of disease-specific scoring models in intensive care patients with severe liver diseases. J Clin Diagn Res,2017,11(6):OC12-OC16.
[14] Bernal W,Jalan R,Quaglia A,et al.Acute-on-chronic liver failure. Lancet,2015,386(10003):1576-1587.
[15] Srikureja W,Kyulo N L,Runyon B A,et al.MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol,2005,124(5):700-708.
[16] Rahimidehkordi N,Nourijelyani K,Nasiritousi M,et al.Model for end-stage liver diseas (MELD) and Child-Turcotte-Pugh (CTP) scores:ability to predict mortality and removal from liver transplantation waiting list due to poor medical conditions. Arch Iran Med,2014,17(2):118-121.
[17] Hoffmann K,Hinz U,Hillebrand N,et al.The meld score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.Langenbecks Arch Surg,2014,399(8):1001-1009.
[18] Jiang M,Liu F,Xiong W J,et al.Combined meld and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol,2010,16(11):1397-1402.
[19] Bie C Q,Yang D H,Tang S H,et al.The value of model for end-stage liver disease and Child-Turcotte-Pugh scores over time in evaluating the prognosis of patients with decompensated cirrhosis:experience in the Chinese mainland. Hepatology,2009,39(8):779-783.
[20] Hsu CY,Lin HC,Huang YH,et al.Comparison of the model for end-stage liver disease(MELD) and MELD-na for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis,2010,42(2):137-142.
[21] Fernández C C,Lens S,Lop E,et al.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD:Analysis of data from the heap-cregistry. Hepatology,2017,65(6):1810-1822.